Dibemethine

Dibemethine

SCHEMBL3425329

CN(Cc1ccccc1)Cc1ccccc1.O=[PH](O)O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
KDM4E B2RXH2 3/20 0.54
TSHR P16473 2/20 0.54
CARM1 Q86X55 1/20 0.53
PRMT6 Q96LA8 1/20 0.53
PRMT8 Q9NR22 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
ACHE P22303 3/20 0.53
BCHE P06276 1/20 0.53
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
LMNA P02545 2/20 0.52
USP2 O75604 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAOA P21397 1/20 0.52
MAOB P27338 1/20 0.52
PYCR1 P32322 1/20 0.52
CA12 O43570 1/20 0.52
CA9 Q16790 1/20 0.52
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dibemethine SCHEMBL10542007 0.86 ALDH1A1 (0.70) ALDH1A1KDM4ETSHRCARM1PRMT6
Dibemethine SCHEMBL276863 0.86 ALDH1A1 (0.70) ALDH1A1KDM4ETSHRCARM1PRMT6
Dibemethine SCHEMBL2139708 0.84 ALDH1A1 (0.67) ALDH1A1KDM4ETSHRCARM1PRMT6
SCHEMBL22305213 0.79 KDM4E (0.61) ALDH1A1KDM4ETSHRCARM1PRMT6
Dibemethine SCHEMBL9416516 0.79 NPC1 (0.63) ALDH1A1KDM4ETSHRCARM1PRMT6
Dibemethine SCHEMBL9416520 0.79 NPC1 (0.63) ALDH1A1KDM4ETSHRCARM1PRMT6
Dibemethine SCHEMBL28224227 0.79 ALDH1A1 (0.56) ALDH1A1KDM4ETSHRCARM1PRMT6
SCHEMBL13052123 0.78 TSHR (0.61) ALDH1A1KDM4ETSHRCARM1PRMT6
SCHEMBL16062223 0.78 ACHE (0.64) ALDH1A1KDM4EACHEBCHENPC1
SCHEMBL4182133 0.78 RAB9A (0.52) ALDH1A1KDM4ETSHRCARM1PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750180-B2 Process for the preparation of N-phosphonomethylglycine and derivatives thereof MONSANTO TECHNOLOGY LLC (US) 2010-07-06 US disclosed
EP-1664068-A2 PROCESS FOR THE PREPARATION OF N-PHOSPHONO-METHYLGLYCINE AND DERIVATIVES THEREOF Monsanto Technology, LLC (US) 2006-06-07 EP disclosed
US-20050054871-A1 Process for the preparation of N-phosphonomethylglycine and derivatives thereof MONSANTO TECHNOLOGY LLC 2005-03-10 US disclosed
WO-2005019230-A2 PROCESS FOR THE PREPARATION OF N-PHOSPHONO-METHYLGLYCINE AND DERIVATIVES THEREOF MONSANTO TECHNOLOGY LLC (US) 2005-03-03 WO disclosed
US-4368162-A Process for producing aminomethylphosphonic acid CIBA-GEIGY CORPORATION (US) 1983-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054871-A1 Process for the preparation of N-phosphonomethylglycine and derivatives thereof PHOSPHO1, GNE, MPHOSPH6 ALDH1A1 4362/4885KDM4E 2415/4885TSHR 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.